malerapaso Introduction Last year, I started covering drug manufacturing giant Amgen Inc. (NASDAQ:AMGN). On June 30, I wrote an article titled "Amgen: A Healthcare Bargain With A 4% Yield." Since then, shares are up 41%, beating the 9.5% performance of the S&P 500 (SP500) by a wide margin. This rally restored the company's longer-term performance, as it is now up 240% over the past ten years (including dividends). This beats the strong performances of the S&P 500 and the Health Care Select Sector SPDR Fund ...

The latest trading session saw Amgen (AMGN) ending at $307.81, denoting a +1.09% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.23% for the day. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 1.7%.Shares of the world's largest biotech drugmaker have appreciated by 9.01% over the course of the past month, outperforming the Medical sector's gain of 3.16% and the S&P 500's gain of 0.94%.The investment community will be closely monitor ...

Amgen (AMGN) ended the recent trading session at $304.08, demonstrating a +0.2% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.56%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq lost 0.59%.Heading into today, shares of the world's largest biotech drugmaker had gained 8.99% over the past month, outpacing the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2% in that time.The investment community will be paying close attention to the earni ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this world's largest biotech drugmaker have returned +11.3%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has gained 8.4%. The key question now is: What could be the stock's future directio ...

The FDA, on Thursday, announced there is no evidence that diabetes and obesity drugs belonging to the popular glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class of medicines cause suicidal thoughts or actions.The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks. GLP-1 drugs are approved f ...

In the latest trading session, Amgen (AMGN) closed at $303.10, marking a -0.48% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.07%.Shares of the world's largest biotech drugmaker have appreciated by 8.15% over the course of the past month, outperforming the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98%.The upcoming earnings release of Amgen will be of great interest to investors. In that report, analysts expect Amgen to post earnings of $4.70 p ...

I am a big fan of routines, as I've found that many poor investment decisions come from an undisciplined use of our time as investors. For me, a weekly scan for stocks making new three-month highs and lows has become a vital part of my own toolkit, as it helps me identify new leadership themes a little earlier on in the trend. I was surprised this week to note the large number of health care names represented on the new highs list. And it wasn't just one group or theme within the sector, but rather a broade ...

“The Dogs of the Dow” system involves purchasing the index’s 10 stocks with the highest dividend yields at the end of each year. Using the technique has a few major advantages. Of course, stocks with high dividend yields pay investors to wait for a rebound to provide either significant income or the ability to buy more shares of stock at no extra cost. Moreover, for the most part, the members of the Dow are profitable leaders in their sectors, so they pose little risk. The members with the highest dividend ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Key PointsAmgen is up +6% so far and is the Nasdaq-100’s second best performing stock year-to-date.At 20x this year’s projected earnings, Regeneron may still be one of the best values in biotech.Gilead Sciences has gone sideways for the better part of the last five years but ended 2023 on an upswing that may have staying power.5 stocks we like better than AmgenUp 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It’s very early, but the sect ...